Neurotoxic thioether adducts of 3,4-methylenedioxymethamphetamine identified in human urine after ecstasy ingestion

Ximena Perfetti, Brian O'Mathúna, Nieves Pizarro, Elisabet Cuyàs, Olha Khymenets, Bruno Almeida, Manuela Pellegrini, Simona Pichini, Serrine Lau, Terrence Monks, Magí Farré, Jose Antonio Pascual, Jesús Joglar, Rafael De La Torre

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) is a widely misused synthetic amphetamine derivative and a serotonergic neurotoxicant in animal models and possibly humans. The underlying mechanism of neurotoxicity involves the formation of reactive oxygen species although their source remains unclear. It has been postulated that MDMA-induced neurotoxicity is mediated via the formation of bioreactive metabolites. In particular, the primary catechol metabolites, 3,4-dihydroxymethamphetamine (HHMA) and 3,4-dihydroxyamphetamine (HHA), subsequently cause the formation of glutathione and N-acetylcysteine conjugates, which retain the ability to redox cycle and are serotonergic neurotoxicants in rats. Although the presence of such metabolites has been recently demonstrated in rat brain microdialysate, their formation in humans has not been reported. The present study describes the detection of 5-(N-acetylcystein-S-yl)-3,4-dihydroxymethamphetamine (N-Ac-5-Cys-HHMA) and 5-(N-acetylcystein-S-yl)-3,4-dihydroxyamphetamine (N-Ac-5-Cys-HHA) in human urine of 15 recreational users of MDMA (1.5 mg/kg) in a controlled setting. The results reveal that in the first 4 h after MDMA ingestion ∼0.002% of the administered dose was recovered as thioether adducts. Genetic polymorphisms in CYP2D6 and catechol-O-methyltransferase expression, the combination of which are major determinants of steady-state levels of HHMA and 4-hydroxy-3- methoxyamphetamine, probably explain the interindividual variability seen in the recovery of N-Ac-5-Cys-HHMA and N-Ac-5-Cys-HHA. In summary, the formation of neurotoxic thioether adducts of MDMA has been demonstrated for the first time in humans. The findings lend weight to the hypothesis that the bioactivation of MDMA to neurotoxic metabolites is a relevant pathway to neurotoxicity in humans.

Original languageEnglish (US)
Pages (from-to)1448-1455
Number of pages8
JournalDrug Metabolism and Disposition
Volume37
Issue number7
DOIs
StatePublished - Jul 2009

Fingerprint

N-Methyl-3,4-methylenedioxyamphetamine
Sulfides
Eating
Urine
Catechol O-Methyltransferase
Cytochrome P-450 CYP2D6
Acetylcysteine
Genetic Polymorphisms
Amphetamine
Oxidation-Reduction
Glutathione
Reactive Oxygen Species
Animal Models
Weights and Measures
Brain

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Perfetti, X., O'Mathúna, B., Pizarro, N., Cuyàs, E., Khymenets, O., Almeida, B., ... De La Torre, R. (2009). Neurotoxic thioether adducts of 3,4-methylenedioxymethamphetamine identified in human urine after ecstasy ingestion. Drug Metabolism and Disposition, 37(7), 1448-1455. https://doi.org/10.1124/dmd.108.026393

Neurotoxic thioether adducts of 3,4-methylenedioxymethamphetamine identified in human urine after ecstasy ingestion. / Perfetti, Ximena; O'Mathúna, Brian; Pizarro, Nieves; Cuyàs, Elisabet; Khymenets, Olha; Almeida, Bruno; Pellegrini, Manuela; Pichini, Simona; Lau, Serrine; Monks, Terrence; Farré, Magí; Pascual, Jose Antonio; Joglar, Jesús; De La Torre, Rafael.

In: Drug Metabolism and Disposition, Vol. 37, No. 7, 07.2009, p. 1448-1455.

Research output: Contribution to journalArticle

Perfetti, X, O'Mathúna, B, Pizarro, N, Cuyàs, E, Khymenets, O, Almeida, B, Pellegrini, M, Pichini, S, Lau, S, Monks, T, Farré, M, Pascual, JA, Joglar, J & De La Torre, R 2009, 'Neurotoxic thioether adducts of 3,4-methylenedioxymethamphetamine identified in human urine after ecstasy ingestion', Drug Metabolism and Disposition, vol. 37, no. 7, pp. 1448-1455. https://doi.org/10.1124/dmd.108.026393
Perfetti, Ximena ; O'Mathúna, Brian ; Pizarro, Nieves ; Cuyàs, Elisabet ; Khymenets, Olha ; Almeida, Bruno ; Pellegrini, Manuela ; Pichini, Simona ; Lau, Serrine ; Monks, Terrence ; Farré, Magí ; Pascual, Jose Antonio ; Joglar, Jesús ; De La Torre, Rafael. / Neurotoxic thioether adducts of 3,4-methylenedioxymethamphetamine identified in human urine after ecstasy ingestion. In: Drug Metabolism and Disposition. 2009 ; Vol. 37, No. 7. pp. 1448-1455.
@article{2f9bf74e37724b06afc0be255cfa16bd,
title = "Neurotoxic thioether adducts of 3,4-methylenedioxymethamphetamine identified in human urine after ecstasy ingestion",
abstract = "3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) is a widely misused synthetic amphetamine derivative and a serotonergic neurotoxicant in animal models and possibly humans. The underlying mechanism of neurotoxicity involves the formation of reactive oxygen species although their source remains unclear. It has been postulated that MDMA-induced neurotoxicity is mediated via the formation of bioreactive metabolites. In particular, the primary catechol metabolites, 3,4-dihydroxymethamphetamine (HHMA) and 3,4-dihydroxyamphetamine (HHA), subsequently cause the formation of glutathione and N-acetylcysteine conjugates, which retain the ability to redox cycle and are serotonergic neurotoxicants in rats. Although the presence of such metabolites has been recently demonstrated in rat brain microdialysate, their formation in humans has not been reported. The present study describes the detection of 5-(N-acetylcystein-S-yl)-3,4-dihydroxymethamphetamine (N-Ac-5-Cys-HHMA) and 5-(N-acetylcystein-S-yl)-3,4-dihydroxyamphetamine (N-Ac-5-Cys-HHA) in human urine of 15 recreational users of MDMA (1.5 mg/kg) in a controlled setting. The results reveal that in the first 4 h after MDMA ingestion ∼0.002{\%} of the administered dose was recovered as thioether adducts. Genetic polymorphisms in CYP2D6 and catechol-O-methyltransferase expression, the combination of which are major determinants of steady-state levels of HHMA and 4-hydroxy-3- methoxyamphetamine, probably explain the interindividual variability seen in the recovery of N-Ac-5-Cys-HHMA and N-Ac-5-Cys-HHA. In summary, the formation of neurotoxic thioether adducts of MDMA has been demonstrated for the first time in humans. The findings lend weight to the hypothesis that the bioactivation of MDMA to neurotoxic metabolites is a relevant pathway to neurotoxicity in humans.",
author = "Ximena Perfetti and Brian O'Math{\'u}na and Nieves Pizarro and Elisabet Cuy{\`a}s and Olha Khymenets and Bruno Almeida and Manuela Pellegrini and Simona Pichini and Serrine Lau and Terrence Monks and Mag{\'i} Farr{\'e} and Pascual, {Jose Antonio} and Jes{\'u}s Joglar and {De La Torre}, Rafael",
year = "2009",
month = "7",
doi = "10.1124/dmd.108.026393",
language = "English (US)",
volume = "37",
pages = "1448--1455",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "7",

}

TY - JOUR

T1 - Neurotoxic thioether adducts of 3,4-methylenedioxymethamphetamine identified in human urine after ecstasy ingestion

AU - Perfetti, Ximena

AU - O'Mathúna, Brian

AU - Pizarro, Nieves

AU - Cuyàs, Elisabet

AU - Khymenets, Olha

AU - Almeida, Bruno

AU - Pellegrini, Manuela

AU - Pichini, Simona

AU - Lau, Serrine

AU - Monks, Terrence

AU - Farré, Magí

AU - Pascual, Jose Antonio

AU - Joglar, Jesús

AU - De La Torre, Rafael

PY - 2009/7

Y1 - 2009/7

N2 - 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) is a widely misused synthetic amphetamine derivative and a serotonergic neurotoxicant in animal models and possibly humans. The underlying mechanism of neurotoxicity involves the formation of reactive oxygen species although their source remains unclear. It has been postulated that MDMA-induced neurotoxicity is mediated via the formation of bioreactive metabolites. In particular, the primary catechol metabolites, 3,4-dihydroxymethamphetamine (HHMA) and 3,4-dihydroxyamphetamine (HHA), subsequently cause the formation of glutathione and N-acetylcysteine conjugates, which retain the ability to redox cycle and are serotonergic neurotoxicants in rats. Although the presence of such metabolites has been recently demonstrated in rat brain microdialysate, their formation in humans has not been reported. The present study describes the detection of 5-(N-acetylcystein-S-yl)-3,4-dihydroxymethamphetamine (N-Ac-5-Cys-HHMA) and 5-(N-acetylcystein-S-yl)-3,4-dihydroxyamphetamine (N-Ac-5-Cys-HHA) in human urine of 15 recreational users of MDMA (1.5 mg/kg) in a controlled setting. The results reveal that in the first 4 h after MDMA ingestion ∼0.002% of the administered dose was recovered as thioether adducts. Genetic polymorphisms in CYP2D6 and catechol-O-methyltransferase expression, the combination of which are major determinants of steady-state levels of HHMA and 4-hydroxy-3- methoxyamphetamine, probably explain the interindividual variability seen in the recovery of N-Ac-5-Cys-HHMA and N-Ac-5-Cys-HHA. In summary, the formation of neurotoxic thioether adducts of MDMA has been demonstrated for the first time in humans. The findings lend weight to the hypothesis that the bioactivation of MDMA to neurotoxic metabolites is a relevant pathway to neurotoxicity in humans.

AB - 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) is a widely misused synthetic amphetamine derivative and a serotonergic neurotoxicant in animal models and possibly humans. The underlying mechanism of neurotoxicity involves the formation of reactive oxygen species although their source remains unclear. It has been postulated that MDMA-induced neurotoxicity is mediated via the formation of bioreactive metabolites. In particular, the primary catechol metabolites, 3,4-dihydroxymethamphetamine (HHMA) and 3,4-dihydroxyamphetamine (HHA), subsequently cause the formation of glutathione and N-acetylcysteine conjugates, which retain the ability to redox cycle and are serotonergic neurotoxicants in rats. Although the presence of such metabolites has been recently demonstrated in rat brain microdialysate, their formation in humans has not been reported. The present study describes the detection of 5-(N-acetylcystein-S-yl)-3,4-dihydroxymethamphetamine (N-Ac-5-Cys-HHMA) and 5-(N-acetylcystein-S-yl)-3,4-dihydroxyamphetamine (N-Ac-5-Cys-HHA) in human urine of 15 recreational users of MDMA (1.5 mg/kg) in a controlled setting. The results reveal that in the first 4 h after MDMA ingestion ∼0.002% of the administered dose was recovered as thioether adducts. Genetic polymorphisms in CYP2D6 and catechol-O-methyltransferase expression, the combination of which are major determinants of steady-state levels of HHMA and 4-hydroxy-3- methoxyamphetamine, probably explain the interindividual variability seen in the recovery of N-Ac-5-Cys-HHMA and N-Ac-5-Cys-HHA. In summary, the formation of neurotoxic thioether adducts of MDMA has been demonstrated for the first time in humans. The findings lend weight to the hypothesis that the bioactivation of MDMA to neurotoxic metabolites is a relevant pathway to neurotoxicity in humans.

UR - http://www.scopus.com/inward/record.url?scp=67649389513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649389513&partnerID=8YFLogxK

U2 - 10.1124/dmd.108.026393

DO - 10.1124/dmd.108.026393

M3 - Article

VL - 37

SP - 1448

EP - 1455

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 7

ER -